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Background: Arterial medial calcification (AMC) is frequent prevalence in patients with end stage renal disease.
Evidence about hyperphosphatemia induced anabolic crosstalk between osteoblast and osteoclast in AMC of
uremia is rare. Lanthanum carbonate as an orally administered phosphate-binding agent to reduce phosphate load
and ameliorate AMC, but direct evidence is missing.
Methods: Detailed time-course studies were conducted of Sprague–Dawley rats fed with adenine and high
phosphate diet to imitate the onset and progression of AMC of uremia. Calcification in great arteries was evaluated
by VonKossa’s and Masson's trichrome staining. Osteoblast (Runx2, Osteocalcin) and osteoclast (RANKL, Cathepsin K,
TRAP) related genes were analyzed by Immunohistochemistry and qRT-PCR. Serum PTH, RANKL and OPG levels
were detected by ELISA kit.
Results: Serum phosphate was markedly increased in CRF group (6.94 ± 0.97 mmol/L) and 2%La group (5.12 ±
0.84 mmol/L) at week 4, while the latter group diminished significantly (2.92 ± 0.73 mmol/L vs CRF Group 3.48 ±
0.69, p < 0.01) at week 10. The rats that did not receive 2%La treatment had extensive von kossa staining for medial
calcification in CRF group. In contrast, the rats in 2%La group just exhibit mild medial calcification. Inhibitory effect
on progression of AMC was reflected by down regulated osteogenic genes and altered osteoclast-like genes.
RANKL/OPG ratio in local calcification area was declined in 2%La group (vs CRF group, p <0.01), whereas marginal
difference in serum among the three groups. In contrast to the robust expression of cathepsinK in calcified area,
TRAP expression was not found.
Conclusions: Abnormal phosphate homeostasis, induction of osteogenic conversion and osteoclast suppression
were contributed to the current mechanisms of uremia associated arterial medial calcification based on our
studies. Beneficial effects of Lanthanum carbonate could be mainly due to the decreased phosphate retention
and cross-talk between osteoblast and osteoclast-like cell, both of which can be the therapeutic target for uremia
associated with AMC.
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Dysmetabolic state uremia perturbs the bone-vascular
axis, giving rise to devastating vascular and skeletal
disease. Arterial medial calcification (AMC) is a well-
defined risk factor for cardiovascular morbidity and
mortality. Patients enter end-stage renal disease and re-
quire dialysis treatment are susceptible to participate in
the onset and progression of calcification in arteries [1].
It generates increased vascular stiffness and reduced vas-
cular compliance, which associated with elevated systolic
pressure and pulse wave velocity. All of these complica-
tions lead to altered coronary perfusion and left ven-
tricular hypertrophy [2]. Accumulating evidence suggest
that arterial calcification is the result of organized and
regulated processes similar to bone formation. Since os-
teoclasts typically function to absorb the bone, it is con-
troversial that the role of osteoclast-like cells in human
calcified lesions. Whether it facilitated vascular calcium/
phosphate accrual or ameliorated vascular calcification is
unclear.
Osteoclasts are specialized cells that develop and ad-
here to bone matrix, then secrete acid and lytic enzymes
that degrade it in a specialized, extracellular compart-
ment [3]. It is plausible that osteoclast- like cells in calci-
fied arteries originate from circulating or locally present
macrophages, particularly in inflammation-driven vascu-
lar calcification. AMC is characterized by linear calcium
phosphate deposits throughout the media layer and oc-
curs independently of intimal atherosclerotic lesions [4].
In fact, it is mysterious for osteoclast-like cells in arterial
medial calcification in ESRD.
Hyperphosphatemia, a disturbed mineral metabolism
contributes to the high calcification burden in artery of
chronic kidney disease patients [5]. Increased phosphate
is known to inhibit osteoclast differentiation and induces
osteoclast apoptosis [6]. Lanthanum carbonate, a new
powerful phosphate binder now is accepted for its dis-
tinct clinical benefits [7,8]. So far however, it is not well
evaluated that the effect of Lanthanum carbonate on
osteoclast-like activity in uremia related arterial medial
calcification. Receptor activator of NF-kB ligand RANKL
is not expressed in normal arteries, but had been de-
tected in atherosclerotic lesions and media calcification.
Likewise, evidence that RANKL stimulates vascular cal-
cification is growing. Denosumab has been studied for
its ability as a monoclonal antibody targeting RANKL to
prevent vascular calcification [9]. It show that RANKL is
required for osteoclast differentiation and survival and
also has direct effects on promoting VSMC calcification
and TRAP+ osteoclast-like cell formation. Osteoproteg-
erin (OPG) in chronic kidney disease patients may act as
a protective mechanism to compensate for bone turn-
over effects of renal failure and appears to be a bridge
between bone tissue and vascular system [10]. It isproduced by osteoblasts and a potent inhibitor of osteo-
clast differentiation by acting as a decoy receptor for
RANKL. RANKL/OPG ratio emerging provides an up-
date on the mechanisms of vascular calcification.
As for the other osteoclastic marker, Cathepsin K and
tartrate-resistant acid phosphatase (TRAP) are two pro-
teins expressed in osteoclastic giant cells, both of which
are involved in degradation of the extracellular organic
matrix during physiologic and pathologic bone remodel-
ing [11]. However, emerging evidence shows their expres-
sion at low levels in extra skeletal tissues, including skin,
muscle and intestines. Further, these classic markers of
osteoclast have been found in atherosclerotic lesions,
prompting us to define their distinct roles in uremic med-
ial calcification. In this study, hyperphosphate-adenine-
enriched diet rat representing typical arterial medial
calcification were considered to be a useful animal
model [12]. We investigate the effect of Lanthanum
carbonate administration on phosphate metabolism and
examined bone-like activities induced by hyperpho-
sphaetmia in arterial medial calcification of uremia.
Method and materials
Animal model
45 healthy Sprague–Dawley rats weighing from 200 to
220 g were randomly divided into three groups: Control
group (group A, n = 15), CRF group (group B, n = 15),
CRF diet supplemented with 2% Lanthanum carbonate
(group C, n =15). Animals were housed 2 per cage under
standardized conditions (25 ± 5°C, 12 h light/dark cycle,
humidity 50 ± 10%). 12 weeks experiment could be di-
vided into three phase. Week −2 to week 0, all the three
groups animals were fed with a basal diet (19% protein),
while Group B and C animals were fed an addition of
1% phosphorus and 1% calcium. Week 0 to week 4, basal
diet (19% protein) of all the animals were replaced with
2.5% protein diet and group B and C were kept on with
1% phosphorus, 1% calcium with 0.75% adenine to in-
duce CRF for 4 weeks [13]. Group C animals were added
2%La in diet since 2nd week. During week 4 to 10, when
adenine withdrawn, 19% protein was as a basal diet
again and group B and C animal were fed the same as
phase 1 until sacrifice (Figure 1). All experiments were
conducted in research center of Provincial Hospital
Affiliated to Shandong University with the approval of
the Institutional Experimental Animal Care and Use
Committee of Shandong University.
Sample collection
Blood samples were drawn from the tail vein were per-
formed at 0, 2, 4 weeks of the rats. At week 10, rats were
sacrificed to be anesthetized with sodium pentobarbital
(50 mg/kg, i.p.) and sagittal laparotomy was performed,
abdominal aorta blood was collected in ice-chilled sterile
Figure 1 Experimental protocol.
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munohistochemical analysis and quantitative calcifica-
tion. Abdominal aorta were washed in saline and
immediately thrown into the liquid nitrogen and stored
in the −70°C refrigerator. Serum creatinine, calcium,
phosphorus and alkaline phosphatase (ALP) were ana-
lyzed using autoanalyzer (Japan, Olympus AU5400),
serum intact PTH (iPTH) was measured using an ELISA
kit from Alpco (Salem, NH). Serum RANKL and OPG
were measured using ELISA kit from EIAab (Catalog
No.E0855r) and CUSABIO (Catalog No.CSB-E07404r)
respectively.
Microscopic evaluation semi-quantitative analysis
Samples immediately were fixed in 10% buffered-formalin
for 24 hour and cut into 4-mm-thick rings that were
embedded upright in the same paraffin block. Every paraf-
fin section composed, on average, 12–14 cross sections at
different sites along the vessel. The histological paraffin
sections were cut to 4 μm thickness and stained with Von
Kossa’s method (magnification × 100). Calcification in
each arterial cross section was scored using the following
semi-quantitative scoring system: 0 none; 1 focal expres-
sion, less than 25% staining; 2 partial expression, 25%-
75% positive staining; 3 circumferential expression. We
stained the three slices adjacent to each section, using
Masson's derived trichrome to stain collagenous regions
(magnification × 200).
Immunohistochemistry
After removal of the paraffin by xylene and dehydration
by graded alcohol, slides were immersed into distilled
water. Arterial cross sections were then transferred into
a 10 mmol/L citrate buffer solution and heated at 80°C
for 5 minutes for antigen retrieval. After washing, 3.0%
peroxide was applied for 20 minutes to block the activity
of endogenous peroxidase. Then slides were incubated
with normal goat serum at room temperature for20 minutes. Primary antibody were anti-Runx2 antibody
(rabbit polyclonal, Abcam), Osteocalcin (rabbit poly-
clonal, SantaCruz Biotechnology, INC), RANKL (goat
polyclonal, SantaCruz Biotechnology, INC), OPG (goat
polyclonal, SantaCruz Biotechnology, INC) and Cathep-
sin K (rabbit polyclonal, Abcam) and TRAP (Clone 9C5,
BioLegend, SanDiego). Secondary antibody was appro-
priately used. Each arterial cross section was graded
semiquantitatively: 0 none; 1 focal expression, less than
25% staining; 2 partial expression, 25%-75% positive
staining; 3 circumferential expression.
RT-PCR
Frozen abdominal aorta tissues were homogenized and
total RNA was extracted with Trizol (Invitrogen, USA)
protocol. The OD260/OD280 ratios were within the range
of 1.8-2.0. Reverse transcription reaction system (TakaRa)
had a total volume of 20 μl and contained 4 μl 5 ×
ExScriptTM buffer, 1 μl dNTP mixture (10 mmol/L), 1 μl
random hexmers (100 μmol/L), 0.5 μl ExScriptTMRtase
(200 U/μl), 0.5 μl RNase inhibitor (40 U/μl), 5–10 μl of
total RNA, and RNase free dH2O. Reaction condition was
42°C 10-15 minutes, 95°C 2 minutes.
Expression of the bone-related proteins were ana-
lyzed by real-time PCR machine (ABI 7000, USA)
using the manufacturer’s protocol (Takara). Probe and
primers were purchased from Taqman gene expression
assays on demand (Applied Biosystems) for GAPDH
(Rn99999916_s1), Runx2 (Rn01512299_m1), Osteocal-
cin (Rn00566386_g1), TRAP (Rn01752289_m1), Cath.k
(Rn00580723_m1), RANKL (NM_057149.1) and OPG
(NM_012870.2). GAPDH served as an internal control,
and all results were expressed as the ratio of target
RNA/GAPDH.
Statistical analysis
Data were analyzed using statistical package SPSS IBM
20.0 and described as mean ± SD. Univariate analysis
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parison between different groups, analysis of variance
was performed followed by one-way analysis of variance
(ANOVA). Correlations were assessed by Pearson correl-
ation test. If the data were not normally distributed, non-
parametric tests were used (Mann–Whitney and Spearman
correlation). p < 0.05 was considered significant.Results
Hampered hyperphosphatemia and varied osteoclast-
associated hormones in serum after 2%La treated
The mortality was low during the whole study and only
one rat was died at week 6 in 2%La group. Table 1
showed biochemical alterations of the three groups of
rats in chronic study. As expected, serum creatinine (Cr)
was similarly increased in uremic rats compared with
normal ones at week 4 (group B 352.7 ± 31.6 μmol/L
and group C 347.3 ± 27.3 μmol/L respectively, p < 0.01).
Serum phosphate was markedly increased in group B
(6.94 ± 0.97 mmol/L) and group C (5.12 ± 0.84 mmol/L)
at week 4, while the latter group diminished significantly
(2.92 ± 0.73 mmol/L) compared with CRF group (3.48 ±
0.69 mmol/L, p < 0.01) at the week 10, but still higher
than normal rats (p < 0.01). Ten weeks of uremia in-
creased serum PTH levels, while treatment with 2%La
did not suppress this at 10th week (1643 ± 115 mmol/L).
Another parameter alkaline phosphatase (ALP) wasTable 1 Serum and urine biochemistry data in different group
Serum index Group 0 W
Creatinine (μmol/L) Con (15) 33.4 ± 14.6
CRF (15) 32.8 ± 14.2
2%La (14) 31.2 ± 15.3
Phosphate (mmol/L) Con (15) 2.45 ± 0.34
CRF (15) 2.61 ± 0.47
2%La (14) 2.52 ± 0.39
Calcium (mmol/L) Con (15) 2.45 ± 0.17
CRF (15) 2.39 ± 0.12
2%La (14) 2.43 ± 0.14
PTH (pg/mL) Con (15) 74.7 ± 35.6
CRF (15) 71.4 ± 32.1
2%La (14) 69.5 ± 29.8
ALP (U/L) Con (15) 34.8 ± 8.7
CRF (15) 35.2 ± 9.3
2%La (14) 34.1 ± 9.8
24-hUrine Phosphate (mmol/L) Con (15) 41.2 ± 18.4
CRF (15) 76.1 ± 23.5a
2%La (14) 72.3 ± 22.4a
aP < 0.01 vs Control Group at the same point.
bP < 0.01 vs CRF Group at the same point.about nine times higher in group B (300.5 ± 19.1 U/L)
than in control group. 2%La treatment of CRF rats re-
sulted in decreases in serum ALP activity (208.9 ± 14.3 U/L,
p < 0.01 vs group B) at 10th week. We also tested the
role of circulating levels of RANKL and OPG as pos-
sible markers for vascular calcification in our model.
OPG was dramatically elevated in group B (2722.4 ±
153.5 U/L) and C (2584.1 ± 147.8 U/L, p < 0.05 vs group B)
at 10th week. Interestingly, the serum level of RANKL was
also markedly elevated that RANKL/OPG ratio was not
modified among the three groups (Table 2).Arterial medial calcification were mitigated along with
bone-associated proteins altered via 2%La treatment
Calcification in great arteries was evaluated by VonKossa’s
and Masson's trichrome staining. The percentage of cross
sections with mild, moderate-to-severe medial calcifica-
tion (ie, scores of 1, 2 and 3 on Von Kossa stained sec-
tions). No evidence showed that calcification existed in
intimae layer and healthy tissue (Figure 2A). Indeed, ex-
tensive medial calcification stained by von kossa was
found in CRF group (Figure 2B). In contrast, the rats in
2%La group just exhibited mild medial calcification
(Figure 2C). These data show that 2%La treatment dra-
matically reduced the medial calcification at the end of
the study (Figure 2G). Masson’s trichrome staining
showed abundant of collagen synthesis in calcifications (x¯± s)
2 W 4 W 10 W
31.3 ± 14.7 34.5 ± 16.9 34.9 ±15.2
164.3 ± 27.9a 352.7 ± 31.6a 203.5 ± 23.6a
159.6 ± 24.4a 347.3 ± 27.3a 194.2 ± 25.7a
2.39 ± 0.41 2.41 ± 0.43 2.51 ± 0.48
3.94 ± 0.73a 6.94 ± 0.97a 3.48 ± 0.69a
3.82 ± 0.67a 5.12 ± 0.84a,b 2.92 ± 0.73a,b
2.42 ± 0.15 2.46 ± 0.19 2.38 ± 0.14
2.47 ± 0.21 2.12 ± 0.27a 1.73 ± 0.26a
2.39 ± 0.18 1.97 ± 0.24a 1.84 ± 0.22a
77.5 ± 33.4 75.3 ± 36.1 79.2 ± 35.4
341.4 ± 45.3a 862 ± 67a 1547 ± 94a
337.6 ± 47.9a 836 ± 54a 1643 ± 115a
36.5 ± 10.2 35.9 ± 10.6 37.7 ± 11.3
39.7 ± 11.6 185.4 ± 17.5a 300.5 ± 19.1a
38.2 ± 9.5 178.9 ± 15.1a 208.9 ± 14.3a,b
42.3 ± 19.6 45.1 ± 17.8 48.5 ± 20.7
59.7 ± 20.3a 39.2 ± 19.1 42.9 ± 18.4
57.2 ± 18.4a 23.3 ± 14.5a,b 27.6 ± 16.7a,b
Table 2 Serum level of RANKL and OPG (x¯± s)
Serum index Group 0 W 2 W 4 W 10 W
RANKL (pg/mL) Con (15) 187.2 ± 27.3 184.1 ± 29.6 189.6 ± 25.5 183.6 ± 23.7
CRF (15) 178. 1 ± 29.2 181.3 ± 32.7 206.3 ± 38.4 305.4 ± 40.2a
2%La (14) 183.9 ± 25.9 179.8 ± 28.1 201.7 ± 31.2 278.3 ± 36.9a
OPG (pg/mL) Con (15) 1956.2 ± 117.3 1894.3 ± 106.4 1931.5 ± 104.9 1912. 3 ± 96.7
CRF (15) 1922.1 ± 98.5 1976.3 ± 95.2 2335.4 ± 114.9a 2722.4 ± 153.5a
2%La (14) 1943.4 ± 105.9 1962.6 ± 100.5 2248.7 ± 134.6a 2584.1 ± 147.8a,b
RANKL/OPG Con (15) 0.09 0.10 0.10 0.09
CRF (15) 0.09 0.09 0.09 0.11
2%La (14) 0.09 0.09 0.09 0.10
aP < 0.01 vs Control Group at the same point.
bP < 0.05 vs CRF Group at the same point.
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2%La (Figure 2D-F). Notably, elastin layers in these cal-
cified areas grossly appeared disorganized and dis-
rupted. Calcification, however, was observed exclusively
in association with areas of severe elastin breaks.
At the molecular level, we analyzed the aorta for evi-
dence of VSMC phenotype change by performing im-
munochemistry. Osteoblast transcription factor Runx2
was a decisive factor identified in calcification process in
different models [14,15]. Runx2 controls the expres-
sion of major osteoblast proteins, such as ALP, Colla-
gen and Osteocalcin [16]. In our study, Runx2 andFigure 2 Representative histochemical micrographs of von Kossa stai
(B) and 2%La group (C), along with Masson-stained (Original magnifi
each arterial cross section was scored as the following semi-quantitative scOsteocalcin were significantly down-regulated in 2%La
group (p < 0.01 vs CRF group) meaned that osteoblast
differentiation were impaired in AMC with 2%La
treatment (Figure 3M-R). Besides, promoted effects of
osteoclast-related proteins were observed. The osteoclasts
were characterized by expression of RANKL, tartrate-
resistant acid phosphatase (TRAP) and Cathepsin K. In
the present study, elevation of early osteoclastic marker
CathepsinK (Figure 3A-C) and RANKL (Figure 3G-I) were
detected in calcified vessels and inversely down regulated
after 2% treatment. RANKL actions are always blocked by
OPG, an amino acid-soluble receptor widely expressed byning (Original magnification × 100) for baseline (A), CRF group
cation × 200) slides from adjacent sections (D-F). Calcification in
oring system (G). All sections were of the thoracic aorta region.
Figure 3 Aorta for evidence of VSMC phenotype change by performing immunochemistry. Expression of CathepsinK (A-C), OPG (D-F),
RANKL (G-I), TRAP (J-L), Runx2 (M-O), and Osteocalcin (P-R) were detected in the aortic tunica media of normal, CRF and 2%La treatment rats.
Arrows indicate positively stained action. All sections were of the thoracic aorta region.
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RANKL/RANK interactions. The RANKL-to-OPG bal-
ance critically determines bone remodeling and net
bone mass. However, exactly what role OPG might play
in vessel calcification is still not understood. In this
work, OPG proteins were almost undetectable in CRF
group (p < 0.01 vs normal group) while the normal ones
and 2%La had a varied extent of expression.
Osteoclasts were also staining positive for TRAP activ-
ity, but neither CRF group nor 2%La group induced
TRAP-positive osteoclasts (Figure 3J-L). Evaluation of
the genes in different group by semiquantitative scor-
ing was demonstrated in Figure 4. A positive correl-
ation of these parameters with the extent of calcification:
Runx2 (r = 0.72, p < 0.01), Osteocalcin (r = 0.76, p < 0.01),
CathepsinK (r = 0.65, p < 0.01), RANKL (r = 0.53, p < 0.05)
were highly correlated with the presence of calcified areas,
while a negative correlation with OPG (r = −0.41, p < 0.05)
was also found.
All the bone related genes except TRAP were involved
in medial calcification with long standing exposure to
hyperphosphatemia and were verified by qRT-PCR.
While the mRNA expression of Cathepsin K, RANKL
and Osteocalcin were highly expressed (p < 0.01 vs Con-
trol), Runx2 was moderately expressed, OPG mRNA was
remarkably down-regulated in CRF group (p < 0.01 vs
Control). Binding of serum phosphate caused signifi-
cantly decrease of Cathepsin K, RANKL, Runx2 and
Osteocalcin expression by 53.9%, 41.7%, 51.4% and
73.3% respectively (p < 0.01 vs CRF group, Figure 5A,C,
E,F) whereas expression of OPG mRNA were found to
be increased 1.7-fold (p < 0.01 vs CRF, Figure 5B). In
addition, while the circulating ratio of RANKL/OPG was
not changed, the local of which exhibited remarkable re-
duction in 2%La group (p < 0.01 vs group B, Figure 5D).
Discussion
In humans, the second most calcified structure after
skeleton is the vasculature and a key issue in vascular
calcification is whether it is reversible or amenable to
therapy. In pilot studies, we found that the rats fed diet
containing 2.5% protein and 0.75% adenine had exten-
sive medial calcification in CRF group. Lower protein
based on casein content of diet can dramatically increase
the frequency and extent of medial artery calcification in
uremic rats [13] and showed higher serum and urinary
phosphate concentration than the grain-based diet [17].
Lanthanum carbonate treatment did not affect renal
function in adenine-treated rats and the reason for the
lack of a renal protective effect in this study might be at-
tributed to the irreversible extensive changes already
established during the adenine treatment 4 weeks. The
2%La treatment markedly lowered serum phosphorus
levels and alleviated the medial calcification in course ofthe investigation. Besides, the prominent PTH along
with severe medial calcification and hyperphosphatemia
well mimic the condition of ESRD patients who were eli-
gible for treatment of Lanthanum carbonate.
Bone remodeling is a predominant metabolic process
in regulating bone structure and function during adult
life, with a key participator being the osteoclast. Regres-
sion of the established vascular calcification is likely to
involve the active osteoclast-like cell regulated process
by stimulating cytokines such as RANKL and inhibitory
cytokines such as OPG. Because of the opposing effects
of RANKL and OPG on bone resorption, the RANKL/
OPG ratio is a major determinant of bone mass and
bone turnover. In vitro experiment, vascular smooth
muscle cells incubated with RANKL showed a dose-
dependent increase in calcification, which was abolished
by co-incubation with OPG [18]. In calcified arterial
media of our model, OPG expression was declined
whereas elevated level of RANKL was observed, leading
to a tendency of increased RANKL/OPG ratio in CRF
rats, the same as the previous report on OPG knocked
out mice [19]. Significantly decreased in RANKL along
with the increased OPG in vascular wall after 2%La
treatment exhibited down regulated RANKL/OPG ratio
in group C (p < 0.01 vs group B) which may be the most
critical mechanism of calcification alleviated. Interest-
ingly, both of serum RANKL and OPG were also mark-
edly elevated that RANKL/OPG ratio was not modified
among the three groups at 10th week which may reflect
the active bone turnover and status of vascular disease.
London et al. found the highest calcification scores in
dialysis patients with the lowest PTH values and histo-
logical signs of adynamic bone disease [20]. Conversely,
in our research most of the uremia rats these exhibit ar-
terial medial calcification had secondary high PTH level
which may contributed to the increased serum RANKL
and OPG level [21]. Including the increased serum ALP,
all of these characters indicated that osteoclast-like cells
were activated in the bone or the vasculature.
Furthermore, we verified the role of osteoclast-like
cells in uremia associated vascular calcification. While
the activated osteoclast in atherosclerotic lesions of
ApoE knockout mice was to facilitate vascular calcium
accrual [22], osteoclast activity in arterial medial calcifi-
cation was unclear. Cathepsin K is one of the main col-
lagenolytic proteinase in osteoclasts. Recently, it has
been shown that osteoblasts produce cathepsin K which
may contribute to collagenous matrix maintenance and
recycling of improperly processed collagen I [23]. One
limitation of our study is that resource of the cathepsinK
expression was not investigated, albeit it was recognized
as an osteoclast marker previously. In contrast to the
robust expression of cathepsin K in calcified area,
osteoclast-like cells that express TRAP were not found in
Figure 4 Evaluation of bone related markers in different groups by semi-quantitative scoring were demonstrated. 0: no expression;
1: focal expression; 2: partial expression; 3: circumferential expression. Immunohistochemical result showed that CathepsinK, RANKL and
Osteocalcin were abundantly expressed whereas Runx2 was moderately expressed (p < 0.01) in CRF rats. Expression of Runx2, CathepsinK, RANKL
and Osteocalcin were significantly down regulated in 2%La group (p < 0.01 vs CRF group). OPG were strongly positive in Control group and
significantly down regulated in CRF group (p < 0.01 vs Control group) and up-regulated in 2%La group (p < 0.05 vs CRF group).
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Large multinucleate osteoclast-like cells have been de-
tected in calcified atherosclerotic lesions [24] media
type calcified lesions of osteoprotegerin (OPG) knock-
out mice [19]. Negative TRAP staining in calcified area
in our study was consistent with the previous reports
that, contrary to atherosclerotic plaque calcification,
in medial calcification macrophage infiltration is notinvolved [18,25]. Higher expression of TRAP might
lead to or result from an inflammatory environment as-
sociated with substantial cell-mediated tissue damage.
In murine collagen induced arthritis, TRAP positive
osteoclast-like cells were detected later in the develop-
ment of bone lesions [26]. The cathepsin K acts within
lysosome to activate TRAP and whether the latter one is a
late marker in vascular lesion remains to be determined.
Figure 5 mRNA expressions of all factors relative to GAPDH were examined by qRT-PCR. Compared to control group, ## (p < 0.01);
Compared to CRF Group, **(p < 0.01). mRNA expression of CathepsinK (A), RANKL (C), Runx2 (E) and Osteocalcin (F) were highly expressed
(p < 0.01 vs control group) along with increased RANKL/OPG ratio (D) while OPG mRNA (B) was down-regulated in CRF group (p < 0.01 vs control).
Binding of serum phosphate caused significantly decrease of CathepsinK, RANKL, Runx2 and Osteocalcin expression by 53.9%, 41.7%, 51.4% and 73.3%
respectively (p < 0.01 vs CRF) whereas expression of OPG mRNA was found to be increased 1.7-fold (p < 0.01 vs CRF). The local RANKL/OPG ratio
exhibited remarkable reduction in 2%La group (p < 0.01 vs CRF).
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seems consistent with the inflammatory nature of athero-
sclerosis because it often accompanied by decreased OPG
and increased RANKL. The same phenomenon occurred
in our arterial medial calcification model, albeit TRAP
negative means no macroghages and even no inflamma-
tion which will attract considerable interest in clinical set-
tings and further investigation.
Similar to the bone formation in which osteoblast-
mediated biomineralization occurs in a matrix based on
the risen synthesis of collagen and decomposed elastin fi-
bers in our study. Inhibitory effect of 2%La on develop-
ment of aortic calcification was reflected by the decreased
expression of Runx2 and Osteocalcin, confirming the
osteogenic activity was significantly inhibited after phos-
phate binding and Lanthanum carbonate could notably
affect osteoblasts via the phosphate regulation. In this
regard, it is reasonable to explain the enhancement ofosteogenic activity and lack of osteoclast activity in calcifi-
cation area. Our studies cannot exclude the possibility that
Lanthanum carbonate acts on TRAP-deficient osteoclast-
like cells led to the osteoblast mediated response. In order
to promote calcification area resorption, cells of the
osteoblast lineage attempt to compensate for the func-
tional defect or lack of osteoclast-like cells by activated
the RANKL pathway, possibly in order to stimulate the
osteoclast activity. Notwithstanding this possibility, the
arterial medial calcification process initiated or speed
up possibly due to osteoclast activity was suppressed or
was not occur in this animal model. Hence an imbal-
ance between the osteoblast and osteoclast processes in
favor of the former one could promote calcification.
Whether the osteoclast-like cells in calcified area to fa-
cilitate vascular calcium accrual or perform a role of
absorbtion in the established vascular calcifications is
largely unanswered.
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Exact mechanism of TRAP negative osteoclast-like cell
in arterial medial calcification is still being elucidated.
The abnormal Ca/Pi homeostasis, failed anti-calcific
events, induction of osteogenic conversion and osteo-
clast deficiency were contributed to the current mecha-
nisms of uremia associated arterial medial calcification
based on our studies. Actually, it depended on a series
of factors, acting alone or in combination, directly in-
fluenced the process of calcium/phosphate deposition
in the arterial wall. Currently no effective treatment is
in general use, the physiological and pharmacological
implications of this dynamic relationship are under-
appreciated. Since the Lanthanum carbonate appears to
play a pivotal role in the osteoblast and osteoclast net-
works, such an approach will provide valuable informa-
tion for the treatment uremia associated arterial medial
calcification.
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